These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31814496)

  • 1. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study.
    Yamaguchi A; Hirata S; Kubo S; Fukuyo S; Hanami K; Nakano K; Nakayamada S; Saito K; Tanaka Y
    Mod Rheumatol; 2020 Sep; 30(5):799-806. PubMed ID: 31814496
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
    Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
    Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
    Kimura N; Suzuki K; Takeuchi T
    Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J; Bastian H; Listing J; Weiß A; Wassenberg S; Liebhaber A; Rockwitz K; Alten R; Krüger K; Rau R; Simon C; Gremmelsbacher E; Braun T; Marsmann B; Höhne-Zimmer V; Egerer K; Buttgereit F; Burmester GR
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Kimura J; Agata N; Takeuchi T
    Arthritis Res Ther; 2017 Mar; 19(1):56. PubMed ID: 28288682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
    Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate.
    Oh K; Ito S; Unno M; Kobayashi D; Azuma C; Abe A; Otani H; Ishikawa H; Nakazono K; Narita I; Murasawa A
    Intern Med; 2015; 54(9):1035-41. PubMed ID: 25948343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE; Kavanaugh A; Florentinus S; Kupper H; Karunaratne M; Birbara CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2188-97. PubMed ID: 26199453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan.
    Tanaka Y; Mimori T; Yamanaka H; Nakajima R; Morita K; Kimura J; Takeuchi T
    Mod Rheumatol; 2019 Jul; 29(4):572-580. PubMed ID: 30009649
    [No Abstract]   [Full Text] [Related]  

  • 14. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.
    Tanaka Y; Mimori T; Yamanaka H; Sunaga N; Morita K; Kimura J; Takeuchi T
    Mod Rheumatol; 2020 May; 30(3):424-433. PubMed ID: 31267801
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients.
    Hamann PDH; Pauling JD; McHugh N; Shaddick G; Hyrich K;
    Rheumatology (Oxford); 2019 Dec; 58(12):2162-2169. PubMed ID: 31155669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission.
    Nawata M; Saito K; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2008; 18(5):460-4. PubMed ID: 18535759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.